Bipolar Disorder in Epilepsy

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by (Responsible Party):
North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT00365482
First received: August 15, 2006
Last updated: May 15, 2012
Last verified: May 2012

August 15, 2006
May 15, 2012
August 2006
December 2011   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00365482 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Bipolar Disorder in Epilepsy
Bipolar Disorder in Epilepsy

The purpose of this study is to find out how often major mood swings occur in patients treated in a specialty epilepsy center.

Bipolar disorder (a condition of major mood swings) or milder forms of ups and downs in mood may occur with a number to neurological conditions. Recently, one study showed that these mood changes occur fairly often in individuals with epilepsy studied in the general community. We speculate that bipolar symptoms occur with even higher frequency in a tertiary epilepsy center than that encountered in the previous community-based study. The goals of this study are to assess:

  • the rate of bipolar symptoms as measured by a self-reporting screening tool in a tertiary epilepsy center setting
  • the meaning of a positive screening score in epilepsy patients
  • the utility, sensitivity and specificity of alternative screening tools for mood instability in epilepsy patients
  • the correlation of mood instability with seizure-related variables
  • the relation of a positive screening score on quality of life.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Epilepsy patients at the Long Island Jewish Comprehensive Epilepsy Center

  • Epilepsy
  • Bipolar Disorder
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
102
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female 18 years of age or older
  • Being evaluated at the Long Island Jewish Comprehensive Epilepsy Center
  • Capable of completing self-reporting questionnaires

Exclusion Criteria:

  • Patients with mental retardation
  • Patients with pseudoseizures
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00365482
06.02.029
No
North Shore Long Island Jewish Health System
North Shore Long Island Jewish Health System
GlaxoSmithKline
Principal Investigator: Sean Hwang, MD Long Island Jewish Medical Center
North Shore Long Island Jewish Health System
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP